Zim Laboratories Limited
Zim Laboratories held its Q4 & FY26 earnings call, reporting a Q4 operating income of Rs.1,053 mn. The company expects a positive outcome from its recent EU GMP re-inspection, with full year operating income at Rs.3,744 mn.
May 23 2026 15:54:47
Zim Laboratories Ltd - 541400 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Zim Laboratories announced the availability of the audio recording for its Q4 & FY26 earnings conference call. Investors can access the recording on the company's official website to review management's discussion on financial performance and outlook.
May 20 2026 20:17:11
Zim Laboratories Ltd - 541400 - Earnings Presentation Q4 & FY26
Zim Laboratories reported Q4 FY26 total operating income of Rs.105.3 cr (down 3.2% YoY) and net profit of Rs.3.7 cr (down 23.4% YoY). Full year FY26 net profit declined 52% YoY to Rs.5.8 cr.
May 19 2026 19:23:11
Zim Laboratories Ltd - 541400 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zim Laboratories' wholly-owned European subsidiary, SIA ZIM Laboratories Limited, Latvia, has received Marketing Authorization (MA) for Dabigatran Etexilate capsules (75, 110, 150 mg) in Italy. This approval, granted by AIFA, opens access to the broader EU market for this product, estimated at USD 392.84 million by 2025.
May 19 2026 18:11:36
Zim Laboratories Limited
Zim Laboratories Ltd's wholly-owned European subsidiary secured Marketing Authorization for Dabigatran Etexilate capsules (75 mg, 110 mg & 150 mg) in Italy. This approval significantly paves the way for faster market entry across the broader European Union and UK markets, targeting an estimated EU market size of USD 392.84 million by 2025.
May 19 2026 18:03:12
Zim Laboratories Ltd - 541400 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 19.05.2026
Zim Laboratories board approved Q4 FY26 cons. financial results, reporting revenue of ₹108.66 cr (up 3.2% YoY) and net profit of ₹4.40 cr (up 17.6% YoY). The board also approved FY26 cons. results with net profit of ₹12.17 cr (up 108.4% YoY) and appointed a Cost Auditor for FY27.
May 19 2026 16:52:55
Zim Laboratories Ltd - 541400 - Board Meeting Intimation for Consideration And Approval Of The Audited Standalone And Consolidated Financial Results For The Year Eneded 31St March, 2026.
Zim Laboratories Board will meet on May 19, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. This meeting will cover both standalone and consolidated results.
May 12 2026 17:06:06
Zim Laboratories Ltd - 541400 - Update - Completion Of EU-GMP Inspection / Audit
ZIM Laboratories informed that the EU GMP inspection of its Nagpur manufacturing facility by German and Portuguese regulatory authorities has been completed. The inspection assessed compliance with European Good Manufacturing Practices.
May 08 2026 17:47:23
Read More